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Abstract
Background: The lysophospholipids sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) are
pleiotropic signaling molecules with a broad range of physiological functions. Targeting the S1P1 receptor on
lymphocytes with the immunomodulatory drug fingolimod has proven effective in the treatment of multiple
sclerosis. An emerging body of experimental evidence points to additional direct effects on cells of the central
and peripheral nervous system. Furthermore, fingolimod has been reported to reduce LPA synthesis via inhibition
of the lysophospholipase autotaxin. Here we investigated whether modulation of particular signaling aspects of
S1P as well as LPA by fingolimod might propagate peripheral nerve regeneration in vivo and independent of its
anti-inflammatory potency.
Methods: Sciatic nerve crush was performed in wildtype C57BL/6, in immunodeficient Rag1−/− and Foxn1−/−
mice. Analyses were based on walking track analysis and electrophysiology, histology, and cAMP formation.
Quantification of different LPA species was performed by liquid chromatography coupled to tandem mass
spectrometry. Furthermore, functional consequences of autotaxin inhibition by the specific inhibitor PF-8380
and the impact of fingolimod on early cytokine release in the injured sciatic nerve were investigated.
Results: Clinical and electrophysiological measures indicated an improvement of nerve regeneration under
fingolimod treatment that is partly independent of its anti-inflammatory properties. Fingolimod treatment
correlated with a significant elevation of axonal cAMP, a crucial factor for axonal outgrowth. Additionally,
fingolimod significantly reduced LPA levels in the injured nerve. PF-8380 treatment correlated with improved
myelin thickness. Sciatic nerve cytokine levels were not found to be significantly altered by fingolimod
treatment.
Conclusions: Our findings provide in vivo evidence for direct effects of fingolimod on cells of the peripheral
nervous system that may propagate nerve regeneration via a dual mode of action, differentially affecting axonal
outgrowth and myelination by modulating relevant aspects of S1P and LPA signaling.
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Background
Lysophospholipids are metabolites of glycerophospholi-
pids and sphingolipids that are commonly found as lipid
constituents of cell membranes. Besides being a structural
membrane component, certain members of the lysopho-
spholipid family have considerable cell signaling proper-
ties [1]. Among these, sphingosine-1-phosphate (S1P) and
lysophosphatidic acid (LPA) and their signaling pathways
have been best characterized. Lysophospholipid signaling
appears to have a large range of physiological and patho-
physiological functions [2, 3] in the adult organism and
also plays important roles during embryonic development,
especially in the development of the nervous system and
vascular development [4–6].
S1P acts as a ligand for five G-protein-coupled recep-
tors [7–11], generally referred to as S1P1–5. Since S1P
receptors couple to a variety of G-proteins, stimulation
of S1P receptors can impact several signal transduction
pathways and cellular processes. In contrast to S1P2–5,
S1P1 is thought to exclusively couple with Gi/o, affecting
cyclic adenosine monophosphate (cAMP) levels and Ca2+
mobilization, among others [10, 12].
Fingolimod (also named FTY720) is a first-in-class
S1P receptor agonist that has been approved for the
treatment of remitting-relapsing multiple sclerosis due
to its immunomodulatory properties [13]. Structurally,
a sphingosine analogue, fingolimod becomes phosphor-
ylated by sphingosine kinases [14] and binds to four of
the five S1P receptors [15], except for S1P2. Its immuno-
modulatory effect is presumably based on its “functionally
antagonistic” effect on the S1P1 receptor expressed on
lymphocytes, causing S1P1 receptor internalization
and subsequently abrogation of S1P1-mediated signal-
ing. It thereby prevents lymphocyte egress [16, 17]. In
addition, phosphorylated fingolimod (fingolimod-P)
has been reported to act as an inhibitor of autotaxin,
an ectonucleotide pyrophosphatase/phosphodiesterase
with lysophospholipase D activity that generates LPA
from more complex lysophospholipids [18]. LPA has
been implicated in dorsal root demyelination after
partial sciatic nerve injury, most likely by activation
of LPA1 receptor signaling [19], and demyelination
has been found to be significantly reduced in heterozygous
autotaxin knockout mice [20]. Furthermore, traumatic
brain injury has been reported to induce significant in-
creases of various LPA species in cerebrospinal fluid
already 3 hours after injury in mice, and administration of
LPA-antibody improves brain tissue damage outcomes
[21]. Additionally, recent publications point to a signifi-
cant role of LPA and LPA1 receptor signaling in the
pathophysiology of spinal cord injuries [22, 23].
As S1P receptors are known to be widely expressed
in the nervous system [24], there is an emerging body
of experimental evidence pointing to direct effects of
fingolimod on cells of the central nervous system [25],
including neuroprotection from excitotoxic death and
the promotion of remyelination. Additionally, fingoli-
mod has been reported to promote functional recovery
in spinal cord injury models [26, 27]. However, the
effects of fingolimod on cells of the peripheral nerve in
vivo have not been investigated so far. To address the
question whether fingolimod may promote peripheral
axon regeneration or remyelination and to differentiate
between potential direct PNS-specific and its estab-
lished immunomodulatory effects, we performed sciatic
nerve crush in wildtype C57BL/6 as well as in two im-
munodeficient mouse strains: Rag1−/− mice lacking ma-
ture B- and T-lymphocytes and in athymic Foxn1−/− mice
devoid of T-lymphocytes. To further explore the role of
LPA during sciatic nerve de- and regeneration as well as
to distinguish the significance of S1P receptor modulation
from LPA mediated effects, we treated animals with the
autotaxin inhibitor PF-8380 [28] and assessed the effect of
fingolimod on LPA formation after injury in sciatic nerve
around the crush site.
Methods
Animals
Rag1−/− mice (B6.129S7-Rag1tm1Mom/J) were obtained
from Jackson Laboratories (Bar Harbor, ME, USA),
Foxn1−/− mice (B6.Cg/NTac-Foxn1nu) from Taconic
(Hudson, NY, USA), and control C57BL/6 mice from
Janvier Labs (Le Genest-Saint-Isle, France). Animal use
and experiments were approved by local authorities
(LANUV North Rhine-Westphalia, Germany).
Sciatic nerve crush
Male, age-matched (3–4 months) wildtype C57BL/6,
Rag1−/−, and Foxn1−/− mice were anesthetized for sur-
gery via intraperitoneal injection of a mixture of xylazine
(Rompun; Bayer, Leverkusen, Germany) (10 mg/kg) and
ketamine (Actavis, Munich, Germany) (100 mg/kg) and
placed on a heating plate (37 °C) to maintain constant
body temperature. The fur of the lower back was re-
moved with an electric razor, and the skin was disin-
fected using 70 % ethanol. All instruments were
sterilized. A small incision (1 cm) was made in the skin
above the right hindlimb between the mm. gluteus
maximus and biceps femoris. Opening the facial plane
between both muscles revealed the sciatic nerve which
was carefully lifted using bent forceps and crushed right
before its distal branches using a non-serrated clamp at
maximum intensity for 30 s. The nerve was replaced
under the muscle, and the incision was closed using
non-absorbable suture material. The contralateral nerve
was left intact to serve as control.
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Administration of fingolimod and PF-8380
Mice received non-phosphorylated fingolimod (FTY720,
Cayman Europe, Tallinn, Estonia) dissolved in a solution
of 10 % DMSO in PBS (Sigma-Aldrich, Munich,
Germany) via intraperitoneal injection at a concentration
of 1 mg/kg once daily over the course of 16 days, starting
2 days before crush until 14 days post-crush. PF-8380
(Sigma-Aldrich) was dissolved in DMSO and administered
at a concentration of 10 mg/kg via intraperitoneal injec-
tion once daily, as well starting 2 days before until 14 days
post-crush. Controls received an equal volume of solvent.
Clinical assessment of nerve functionality by walking
track analysis
Nerve functionality was assessed 2 days before as well as 7
and 14 days post-crush by walking track analysis and cal-
culation of the sciatic functional index (SFI) as described
elsewhere [29].
Electrophysiology
Electrophysiology was essentially performed as described
previously [30]. Nerve conduction velocities and com-
pound muscle action potentials were determined at
14 days post-crush. Mice were anesthetized with a mix-
ture of ketamine (100 mg/kg) and xylazine (10 mg/kg)
and immediately placed on a heating plate (37 °C) to
maintain constant body temperature. Stimulation of the
sciatic nerve was performed by repetitively generated
single pulses using monopolar 30 G needle electrodes
until supramaximal stimulation was achieved. Com-
pound muscle action potential was recorded at the
plantar foot muscle with a needle electrode using a
portable electrodiagnostic system (KeyPoint 4, Medtro-
nic, Meerbusch, Germany). Nerve conduction velocity
was calculated from the distance and the motor latency
differences between proximal and distal stimulations.
Tissue preparation
Following electrophysiology, mice were sacrificed via cer-
vical dislocation. Sciatic nerves were carefully removed by
only handling the most proximal end with forceps and
cutting the nerve at its most distal end using scissors. For
immunohistochemical applications, the nerves were
immediately dipped in an isopentane bath immersed in
liquid nitrogen for approximately 5 s. Then frozen
nerves were placed in suitable cryomolds, covered with
a cryo-embedding compound and placed on dry ice.
Embedded nerves were stored at −80 °C. Longitudinal
sections of 7-μm thickness were prepared in a cryostat
chamber, and slides were air-dried for at least 1 hour
before further processing or stored at −20 °C.
Antibodies
The following antibodies were used and diluted in Anti-
body Diluent (Dako, Hamburg, Germany) as indicated:
Rabbit anti-cAMP polyclonal antibody—1:50 (Merck-Milli-
pore, Darmstadt, Germany); biotinylated goat anti-rabbit
IgG—1:200 (Vector Laboratories, Peterborough, UK);
DyLight 594 Streptavidin—1:200 (Vector Laboratories);
rabbit anti-neurofilament L (NF-L)—1:1000 (Merck-
Millipore); and Alexa Fluor 488 Goat Anti-Rabbit
IgG—1:200 (Life Technologies).
Immunofluorescence
Sections were post-fixed in 4 % paraformaldehyde for
20 min. After fixation, slides were washed 5 min in PBS
and twice for 5 min in PBT (PBS + 0.1 % Triton X-100).
Slides were incubated with blocking solution (10 % nor-
mal goat serum (v/v) in PBT) for 30 min at room
temperature. For the detection of cAMP, primary anti-
body was applied and slides were incubated at 4 °C for
16 h. Slides were washed twice for 5 min in PBT, and bi-
otinylated secondary antibody was applied and incubated
at room temperature for 1 hour. Slides were washed
twice for 5 min in PBT, and DyLight594-conjugated
streptavidin was applied. If desired, co-staining with
NF-L was performed. Slides were washed 2 × 5 min in
PBT and incubated with anti-NF-L antibody at room
temperature for 1 hour. Slides were washed twice for
5 min and incubated with Alexa Fluor 488-conjugated
secondary antibody. Slides were washed 5 min in PBT
and 5 min in PBS and mounted with Vectashield
Hardset mounting medium containing DAPI (Vector
Laboratories).
Preparation of semi-thin sections
Nerves were fixed in 0.1 M cacodylate buffer containing
2.5 % glutaraldehyde and kept at 4 °C overnight. The
fixative was discarded and replaced by washing buffer
(0.1 M cacodylate + 3 % sucrose). Nerves were washed
for 4 days at 4 °C. Washing was followed by incubation
in an osmium tetroxide reagent for 3 h. Osmium tetroxide
reagent was composed of one part 5 % potassium dichro-
mate solution (pH 7.4), one part 3.4 % NaCl solution, and
two parts 2 % osmium tetroxide solution (Sigma-Aldrich).
Afterwards, samples were briefly washed in 0.1 M cacody-
late buffer.
Samples were dehydrated in an ascending ethanol
series (70 %; 96 %; ≥99.8 % undenatured ethanol) for
1 hour each. Following dehydration, samples were incu-
bated in 250 μl propylene oxide (Sigma-Aldrich) in tightly
closed containers for 1 hour at room temperature, then
1 hour in a 1:1 mixture of propylene oxide/epon (epoxy
embedding medium kit; Sigma-Aldrich), and finally kept
at 4 °C in epon only overnight. Samples were placed in
silicone molds and covered with epon embedding mixture.
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Embedded samples were incubated at 37 °C for 6 h, at
47 °C for 15 h, and finally at 60 °C for 28 h until epon
was completely hardened. Transverse sections were
prepared at a thickness of 1 μm at a Reichert-Jung
Ultracut Microtome and immediately stained with
toluidine blue (1 % toluidine blue (w/v) dissolved in a
1 % disodium tetraborate (w/v) solution), washed in
distilled H2O (approximately 10 ml) containing 1–2
drops of acid ethanol (0.01 % HCl in absolute ethanol),
placed on a microscope slide, dried on a heating plate,
and mounted with Roti Histokitt II (Roth).
Quantification of LPA by liquid chromatography coupled
to tandem mass spectrometry (LC-MS/MS)
Sciatic nerve homogenates were extracted using 800 μl
of a mixture methanol:chloroform (2:1) (both VWR
International, Darmstadt, Germany) after addition of
20 μl LPA 17:1 (1 μg/ml) (Avanti Polar Lipids, Alabaster,
AL, USA) as internal standard (IS), 50 μl deionized
water (VWR), and 40 μl 6 M HCl (Merck, Darmstadt,
Germany). Samples were vortexed for 5 min and incu-
bated 20 min at -20 °C. After centrifugation (10 min,
14,000×g), the upper phases were transferred to new
sample tubes and extracted with 200 μl chloroform
(Merck) and 250 μl deionized water. Samples were vor-
texed rigorously and centrifuged for 10 min at 14,000×g.
The lower organic phases were dried under nitrogen gas
flow at 60 °C. The dried residues were dissolved in 50 μl
LC-MS grade methanol (mobile phase B). Analysis was
performed on a Waters/Acquity ultra performance LC-
MS system controlled with MassLynx software. Analysis
was operated with electrospray ionization (ESI) probe in
negative ESI employing multiple reaction monitoring
(mrm) mode. LPA species for the establishment of mrm
experiments were obtained from Avanti Polar Lipids.
The following transitions were used: m/z 435 [M-H-] to
153 (LPA 18:1), m/z 409 [M-H-] to 153 (LPA 16:0), m/z
437 [M-H-] to 153 (LPA 18:0), and m/z 421 [M-H-] to
153 for the internal standard (LPA 17:1). Collision en-
ergy (ce) and cone voltage (cv) were both set to 30 V for
all mrm experiments. The column used for chromatog-
raphy was a Thermo Scientific Hypersil Gold, 1.9 μm,
50 × 2.1 mm column. A total flow rate of 0.4 ml/min
was applied with an injection volume of 10 μl. The mo-
bile phases consisted of 5 mM ammonium formate
(Sigma-Aldrich) buffered water (A) and methanol (B),
both containing 0.1 % formic acid (Sigma-Aldrich). Gra-
dient elution was performed starting at 50 % mobile
phase B applying isocratic conditions for 2.5 min and
then progressing to 100 % B over 3 min. 100 % B was
held up for 2 min. Within 1 min, the gradient increased
linear to initial conditions and was held up to 10 min
for re-equilibration. Column temperature was adjusted
at room temperature (25 °C ± 5 °C). The autosampler
operated at 10 °C. Run time was set to 10 min. Retention
times of LPA species were 2.99 min (LPA 18:1),
2.95 min (LPA 18:0), 3.10 min (LPA 16:0), and 2.17 min
(LPA 17:1 IS), respectively. Data analysis was performed
using peak-area-ratios of analytes to internal standard.
Determination of nerve cytokine levels by ELISA
For the detection of cytokines, commercially available
ELISA kits (Duo Set mouse TNF-α, R&D Systems,
Minneapolis, MN, USA; Mouse IL-10 ELISA MAX
Standard Set, Biolegend, San Diego, CA, USA) were
used essentially as instructed. Briefly, sciatic nerves
were homogenized in 250 μl ice-cold PBS containing
cOmplete™ Mini (Roche, Basel, Switzerland) proteinase
inhibitor cocktail. Homogenates were centrifuged for
10 min at 11,000 rpm, and supernatants were trans-
ferred to new sample tubes, diluted 1:2 with assay buffer
(PBS containing 1 % BSA and 0.1 % Tween20) and vor-
texed rigorously. Detection of cytokines was performed as
recommended by the manufacturers. Sciatic nerve cyto-
kine content was normalized to the respective protein
content of the sample.
Image and data analysis
Analysis of images was performed using ImageJ (National
Institutes of Health, Bethesda, MA, USA). Data analysis
and compilation of graphs was performed using Microsoft
(Redmond, WA, USA) Excel and GraphPad (La Jolla, CA,
USA) Prism 5. Statistical analysis was done by Student’s t
test, multiple comparisons were performed by one-way
ANOVA followed by the Newman-Keuls post hoc test or
Kruskal-Wallis test and Mann-Whitney U test for non-
Gaussian distributions. Statistical significance is indicated
by asterisks with P ≤ 0.05*, P ≤ 0.01**, and P ≤ 0.001***.
Results
Impact of fingolimod on electrophysiological and clinical
measures after injury
We performed sciatic nerve crush in immunocompetent
wildtype and in immunodeficient T- and B-lymphocyte
deficient Rag1−/− as well as in T-lymphocyte deficient
Foxn1−/− mice to identify lymphocyte-independent effects
of fingolimod on peripheral nervous system regeneration.
Fingolimod treatment resulted in significantly increased
nerve conduction at 14 days post-crush in wildtype
C57BL/6 mice (Fig. 1a). This finding is consistent with
significantly improved functional recovery as determined
by walking track analysis and SFI (Fig. 1c). In contrast,
Rag1−/− mice did not show an improvement of nerve re-
generation by clinical or electrophysiological measures
neither with fingolimod nor DMSO-only treatment
(Fig. 1a, c), and DMSO-treated control Rag1−/− mice even
exhibited some additional mean, however, non-significant
decline in SFI (Fig. 1c). However, Foxn1−/− mice, which
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are devoid of T- but not B-lymphocytes, did show an
improvement of nerve regeneration under fingolimod
treatment (Fig. 1a, c). Although the mean increase in
nerve conduction velocity in both fingolimod-treated
and control Foxn1−/− mice implies a potentially positive
role of T-lymphocyte deficiency on nerve regeneration,
only fingolimod-treated Foxn1−/− mice showed a signifi-
cant improvement compared to C57BL/6 controls and
performed better in the functional analysis (Fig. 1a, c).
Effect of fingolimod on axonal cAMP levels
To better understand potentially relevant molecular
mechanisms by which fingolimod may exert the observed
neuroregenerative effects, we investigated cAMP, an
axonal outgrowth enhancing factor that accumulates
proximal from and around the injury site during axonal
regeneration [31–34]. We hypothesized that fingolimod
causes abrogation of S1P1-mediated signaling through
S1P1 receptor internalization in cells of the peripheral
nerve, thereby indirectly increasing cAMP levels by re-
duced inhibition of adenylate cyclase. Quantification of
cAMP immunofluorescence proximal from and around
the injury site at 14 days post-crush revealed significantly
increased cAMP levels under fingolimod treatment in
C57BL/6 and Foxn1−/− mice (Fig. 2a–c), and this increase
in cAMP paralleled significantly improved clinical and
Fig. 1 Fingolimod (FTY720) improves peripheral nerve regeneration by electrophysiological and clinical measures. a C57BL/6 as well as Foxn1−/− mice
treated with fingolimod were found to display significantly improved nerve conduction velocities (NCV) compared to wildtype controls. Rag1−/− mice
did not show an improvement of nerve regeneration by this measure. Statistical analysis was done by Kruskal-Wallis test and Man-Whitney U
test. N = 11/13/11/11/15/17 animals (from left to right). b Nerve conduction was normal in contralateral non-crushed nerves of the same
animals. c Assessment of functional recovery was determined by walking track analysis via sciatic functional indices (SFI). Two days before
crush sciatic nerve function was normal in all three mouse strains. Seven days post-crush nerve function was significantly impaired in all three mouse
strains (P≤ 0.01) as indicated by a decline in SFI. Note that Rag1−/− control mice showed an additional mean, but non-significant worsening of nerve
function. At 14 days post-crush, significantly improved nerve conduction is consistent with significantly improved SFI in fingolimod-treated C57BL/6
and Foxn1−/− animals. No significant difference in SFI was observed in Rag1−/− mice at this stage. N = 8/9/7/6/9/14 animals minimum for each graph
(from left to right). Statistical analysis was done by Student’s t test, two-tailed. Data represent mean ± s.e.m. Statistical significance is indicated by
asterisks with P≤ 0.05*, P≤ 0.01**, and P≤ 0.001***
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electrophysiological measures in these animals (Fig. 1). In
contrast, Rag1−/− mice did not show a relevant elevation
of cAMP levels under fingolimod treatment when com-
pared to wildtype or Foxn1−/− controls and cAMP levels
were even significantly reduced in fingolimod-treated
Rag1−/− compared to fingolimod-treated C57BL/6 and
Foxn1−/− mice. Strikingly, overall reduced axonal cAMP
correlates with impaired regeneration in fingolimod-
treated Rag1−/− mice.
Myelin thickness after injury and inhibition of autotaxin
Following peripheral nerve injury, myelin sheaths of re-
generated axons are commonly found to be significantly
thinner compared to those of contralateral control
nerves [35]. Therefore, to assess the effect of fingolimod
on myelin thickness after injury, we performed g-ratio
(the numerical ratio between the diameter of the axon
and the diameter of the outer myelinated fiber) measure-
ments from semi-thin sections prepared from the distal
stump of injured and control nerves at 14 days post-
crush (Fig. 3a). Analysis of g-ratios revealed significantly
decreased myelin thickness in crushed nerves of control
animals compared to myelin thickness in contralateral
non-crushed nerves whereas myelin thickness was signifi-
cantly increased in crushed nerves of fingolimod-treated
mice (Fig. 3b). This was also the case in Rag1−/− mice.
Fig. 2 Fingolimod (FTY720) significantly elevates cAMP levels in the regenerating nerve. a Fourteen-day post-crush, colocalization of cAMP and
neurofilament light-chain immunohistochemistry indicates an accumulation of axonal cAMP around and proximal from the injury site. b Representative
images of cAMP immunofluorescence. Scale bar indicates 100 μm. c Quantification of cAMP immunofluorescence revealed significantly increased
axonal cAMP levels in crushed nerves under fingolimod treatment in wildtype mice and both immunodeficient mouse strains. Note that although
fingolimod induced a significant cAMP increase in Rag1−/− mice compared to Rag1−/− controls, overall cAMP levels were reduced in Rag1−/− mice,
which correlates with the impairment of regenerative capacity in these mice. N = 4/4/6/4/4/6 animals (from left to right; quantification of one
representative slide per animal). Statistical analysis was done by one-way ANOVA and Newman-Keuls post hoc test. Data represent mean ± s.e.m.
Statistical significance is indicated by asterisks with P≤ 0.05*, P≤ 0.01**, and P≤ 0.001***
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Therefore, we hypothesized that fingolimod may improve
myelin thickness by diminishing LPA levels in the injured
nerve via inhibition of autotaxin. We assessed LPA levels
in the sciatic nerve of C57BL/6 mice at 3 and 24 h
post-crush under DMSO and fingolimod treatment.
Analysis of sciatic nerve LPA content by LC-MS/MS
Fig. 3 Fingolimod (FTY720) enhances myelin thickness independent of its immunomodulatory properties. a Representative images of semi-thin
sections used for g-ratio measurements. b G-ratios indicate significantly reduced myelin thickness in crushed nerves of C57BL/6 and Rag1−/− control
animals compared to myelin thickness of contralateral non-crushed nerves. Fingolimod-treated mice showed a reciprocal ratio, with slightly, but even
significantly increased myelin thickness in crushed nerves compared to contralateral non-crushed nerves. N = 5/5/4/4/4/4/4/4 animals (from left to
right, quantification of one slide per animal). c Treatment of C57BL/6 mice with the autotaxin inhibitor PF-8380 prevented the significant reduction in
myelin thickness in regenerating axons normally observed after crush injury (N = 4/4 animals, quantification of one slide per animal). d Representative
images of semi-thin sections used for g-ratio measurements at 14-day post-crush in PF-8380 treated mice. e PF-8380 treated C57BL/6 mice did not
show an improvement in nerve conduction at 14-day post-crush, pointing to no effect of autotaxin inhibition on axonal regeneration (N = 4/4
animals). f Fingolimod significantly reduces sciatic nerve concentration of 16:0 and 18:0 LPA at 3-h post-injury in crushed nerves of C57BL/6
mice. LPA concentration is still reduced in average at 24-h post-crush. However, in DMSO-treated control mice, nerve injury did not induce
invariably increased LPA levels in the crushed nerve compared to contralateral non-crushed nerves. LPA levels are depicted as a ratio calculated from
LPA in the crushed nerve and the corresponding contralateral non-crushed nerve (LPAc/LPANC) to account for individual LPA levels between different
animals. (N = 4 for each column). g PF-8380 significantly reduces LPA levels at 3-h post-injury in crushed nerves of C57BL/6 mice (N = 5 animals for
each column (3 h) or four animals for each column (24 h), respectively) (C crushed, NC non-crushed). Statistical analysis was done by Student’s t test,
two-tailed. Data represent mean ± s.e.m. Statistical significance is indicated by asterisks with P≤ 0.05*, P≤ 0.01**, and P≤ 0.001***
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revealed significantly reduced LPA levels at 3 h post-
crush in fingolimod-treated mice (Fig. 3f ). Twenty four
hours post-crush LPA levels were still lower in average,
though not significantly. However, LPA levels were not
found to be invariably increased in the crushed nerves
of DMSO-treated control mice, indicating that physio-
logical LPA levels produced by autotaxin may be suffi-
cient to induce demyelination after injury. To evaluate
the functional consequence of LPA reduction, we
assessed myelin thickness in C57BL/6 mice treated with
the specific autotaxin inhibitor PF-8380. G-ratio measure-
ments from semi-thin sections obtained at 14 days post-
crush revealed normal and strikingly not significantly re-
duced myelin thickness in distal regenerating axons
(Fig. 3c), pointing to a role of LPA in demyelination or
downregulation of myelin proteins, respectively. Finally, to
distinguish LPA from S1P-mediated effects on axonal re-
generation, we performed electrophysiology with ani-
mals treated with PF-8380 at 14 days post-crush. We
could not detect any signs of improved nerve conduction
in these mice, suggesting that inhibition of autotaxin and
lowering LPA levels, respectively, may primarily affect
myelination, but not peripheral axon regeneration (Fig. 3e).
Sciatic nerve cytokine levels after injury
Since cytokines are known to potentially impact nerve
regeneration [36, 37], we finally tested whether fingoli-
mod affects sciatic nerve levels of the pro-inflammatory
cytokine tumor necrosis factor alpha (TNF-α) and the
anti-inflammatory cytokine interleukin 10 (IL-10), which
are both known to be highly expressed at 24-h post-injury
[38]. We recognized a significant increase of both TNF-α
and IL-10 levels after injury but could not find fingolimod
to significantly affect this cytokine response (Fig. 4).
Discussion
In this work, we provide in vivo evidence for direct effects
of the S1P receptor agonist fingolimod on the peripheral
nervous system that may result in the promotion of per-
ipheral nerve regeneration. Although certain positive ef-
fects of fingolimod-induced T-lymphocyte sequestration
on nerve regeneration cannot be ruled out completely,
our data strongly indicate that direct effects of fingolimod
on neurons and Schwann cells are responsible for im-
proved nerve regeneration. Fingolimod treatment was
associated with a significant elevation of axonal cAMP, a
crucial factor for central and peripheral axon regeneration
[31–34]. The observed increase in cAMP may most likely
be the result of fingolimod-induced S1P1 receptor in-
ternalization in cells of the peripheral nerve that may
cause the abrogation of S1P1-mediated inhibition of ad-
enylate cyclase. It has been proposed that the S1P1-Gi-
adenylate cyclase system may become internalized as a
ternary complex, leading to sustained inhibition of ad-
enylate cyclase as long as the ligand fingolimod-P is
bound [39]. However, we propose differences between
“short-term” (several hours) and “long-term” (several
days to weeks) administration of fingolimod as, in con-
trast to inhibition of cAMP formation in cell culture
experiments by sustained signaling from intracellular
compartments [40], our data demonstrate that long-
term administration of fingolimod in vivo may result in
an elevation of cAMP. The internalized S1P1-Gi-adenyl-
ate cyclase system is likely to become degraded over
time, and constantly high concentrations of fingolimod-
P may prevent the localization of de novo synthesized
S1P1 to the plasma membrane. Hence, the pivotal differ-
ence in the long-term situation may be the spatial segrega-
tion of S1P1 and adenylate cyclase, consequently allowing
for an increased cAMP response in the regenerating
Fig. 4 Fingolimod (FTY720) does not alter pro- and anti-inflammatory cytokine levels after injury. Neither sciatic nerve levels of TNF-α (a) nor IL-10
(b) were found to be significantly affected by fingolimod treatment at 24 h post-crush. Baseline sciatic nerve cytokine levels were determined in
naive mice. N = 3/3/11/9 animals for each graph, from left to right. Statistical analysis was done by Student’s t test, two-tailed; n.s. indicates no
significant difference. Data represent mean ± s.e.m
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nerve. Clearly, further studies are needed to corrobor-
ate this assumption.
In contrast to T-lymphocyte-deficient Foxn1−/− mice
which exhibited signs of significantly improved nerve
regeneration under fingolimod treatment, B- and T-
lymphocyte deficient Rag1−/− mice did not show an
improvement of nerve regeneration, neither with fingoli-
mod nor vehicle treatment. Although one recent study
has reported evidence for improved nerve regeneration
after femoral nerve injury in Rag2−/− mice which lack
functional T- and B-lymphocytes as well [41], others have
found nerve regeneration and motor neuron survival to
be reduced in Rag2−/− mice [42], which is in line with our
observations in Rag1−/− mice. The idea of an overall re-
duced regenerative capacity of Rag1−/− mice is further
supported by the finding that B-lymphocytes appear to be
required for the production of autoantibodies against
myelin debris containing inhibitors of axonal outgrowth,
consequently allowing for normal axonal regeneration
after nerve injury [43]. Myelin-associated inhibitors of
axonal outgrowth have been implicated in reducing neur-
onal cAMP in a Gi-dependent manner via activation of
the Nogo receptor-p75 neurotrophin receptor complex
[44], providing a likely explanation for significantly re-
duced axonal cAMP in response to fingolimod treatment
and, consistently, the impaired regenerative capacity ob-
served in Rag1−/− mice due to the lack of B-lymphocytes.
Although fingolimod is known to also reduce the number
of circulating B-lymphocytes, it has recently been shown
to increase the proportion of regulatory B-lymphocytes
producing IL-10. While we could not detect a signifi-
cant elevation of IL-10 nor a decrease in TNF-α levels
in the sciatic nerve of fingolimod-treated mice at 24-h
post-crush (Fig. 4), an increase in IL-10 secreting B-
lymphocytes may occur at later stages and could poten-
tially contribute to accelerated nerve regeneration [37, 45].
However, despite decreased cAMP, Rag1−/− mice still
showed significantly improved myelin thickness. An-
other member of the lysophospholipid family, LPA, was
found to be significantly reduced in the crushed nerve
in fingolimod-treated mice shortly after injury. Strik-
ingly, inhibition of autotaxin by the specific inhibitor
PF-8380 prevented the significant reduction of myelin
thickness normally observed after peripheral nerve injury.
Although LPA levels were not invariably and not signifi-
cantly increased in control mice, it appears unlikely that a
sole increase in LPA would account for demyelination, but
rather an elevated expression of the LPA1 receptor after
injury. In this context, it has been reported that the LPA1
receptor is upregulated within the first days after sciatic
nerve injury in the distal nerve stump, and this upregula-
tion is accompanied by an abrupt downregulation of the
myelin gene P0 [46]. In line with this, a single intrathecal
injection of LPA or nerve injury was found to cause a
decrease in the expression of the myelin proteins PMP22
and MBP, but the demyelinating effect was largely abol-
ished in LPA1-null mice [19]. Furthermore, antagonism of
the LPA1 receptor has recently been demonstrated to
reduce demyelination after spinal cord injury [21]. There-
fore, improved myelination could be a consequence of
both fingolimod as well as PF-8380-mediated inhibition of
autotaxin, attenuating LPA1 receptor activation via re-
duced LPA synthesis. Although autotaxin represents
only one of multiple metabolic pathways to produce
LPA, autotaxin appears to be one major contributor to
LPA synthesis after injury, as it was previously shown
that injury-induced dorsal root demyelination is signifi-
cantly reduced in heterozygous autotaxin knockout
mice [19]. However, since PF-8380 treatment did not
lead to signs of improved axonal regeneration, our re-
sults might suggest a dual mode of action for fingoli-
mod in peripheral nerve regeneration—fingolimod may
promote axonal regeneration by indirectly elevating
cAMP formation as a consequence of S1P1 receptor in-
ternalization and may prevent LPA-induced downregu-
lation of myelin gene expression in the regenerating
nerve. Further studies are warranted to corroborate this
assumption.
Conclusions
Collectively, our data presented here demonstrate that
modulation of lysophospholipid signaling in the peripheral
nervous system by fingolimod may enhance nerve regener-
ation by acting on multiple molecular and cellular levels
and partly independent of its anti-inflammatory effects. In
addition to the established role of fingolimod as a modula-
tor of S1P receptor-mediated signaling, the inhibition of
LPA synthesis after injury may represent a yet unrecognized
mechanism that contributes to the presumptive remyelinat-
ing effect of fingolimod.
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